

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/718,262
	Filing Date	November 20, 2003
	First Named Inventor	Paul B. McCray, Jr. et al.
	Art Unit	1636
	Examiner Name	David Guzo
	Attorney Docket Number	17023.035US1
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Form 1449 (2 pgs.); Copies of 19 cited references; Comm. Concerning Related Applications (1 pg.); Check for \$180.00 for IDS fee; return postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	VIKSINIS HARRIS & PADYS PLLP		
Signature			
Printed name	Peter L. Malen		
Date	April 10, 2006	Reg. No.	44,894

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Lynda Mau	Date	April 10, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



S/N 10/718,262

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul B. McCray, Jr. et al. Examiner: David Guzo
Serial No.: 10/718,262 Group Art Unit: 1636
Filed: November 20, 2003 Docket: 17023.035US1
Title: METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED
RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC
CHORIOMENINGITIS VIRUS (LCMV)

COMMUNICATION CONCERNING RELATED APPLICATIONS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Applicants would like to bring to the Examiner's attention the following related application.

Applications that claim priority to the related application may be filed, and Applicants respectfully request that the Examiner review those applications prior to issuing a Notice of Allowance in the present application.

Application Number	Filing Date	Docket Number
10/993,319	November 19, 2004	17023.051US1

Respectfully submitted,
Paul B. McCray, Jr. et al.
By their Representatives,
Viksnins Harris & Padys PLLP
P.O. Box 111098
Saint Paul, MN 55101
952 876-4094

Date April 10, 2006

By 
Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of April, 2006.

Lynda Mau
Name


Signature

S/N 10/718,262

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Paul B. McCray, Jr. et al. Examiner: David Guzo
Serial No.: 10/718,262 Group Art Unit: 1636
Filed: November 20, 2003 Docket: 17023.035US1
Title: METHODS FOR PRODUCING AND USING IN VIVO PSEUDOTYPED
RETROVIRUSES USING ENVELOPE GLYCOPROTEINS FROM LYMPHOCYTIC
CHORIOMENINGITIS VIRUS (LCMV)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.


An Information Disclosure Statement filing fee of \$180.00 is enclosed herewith. The Commissioner is hereby authorized to charge any additional required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
Paul B. McCray, Jr. et al.
By their Representatives,
Viksnins Harris & Padys PLLP
P.O. Box 111098
Saint Paul, MN 55111
952 876-4094

04/14/2006 SFELEKE1 00000091 10718262


01 FC:1806 180.00 DP

Date April 10, 2006


By 
Peter L. Malen
Reg. No. 44,894

CERTIFICATE UNDER 37 CFR 1.8: I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450, Alexandria, VA 22313-1450, on this 10th day of April, 2006.

Lynda Mau
Name


Signature

Substitute for form 1449A/PTO and/or 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Complete if Known

Application Number	10/718,262
Filing Date	November 20, 2003
First Named Inventor	McCray
Group Art Unit	1636
Examiner Name	David Guzo

Sheet 1 of 2

Attorney Docket No: 17023.035US1

US PATENT DOCUMENTS

Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document
	6,440,730	August 27, 2002	Von Laer et al.
	6,555,107	April 29, 2003	Poeschla et al.
	2005/0123517	June 09, 2005	McCray, Jr. et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)
	WO 03/092582	November 13, 2003	
	EP 1 006 196	June 07, 2000	Abstract

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).
	International Search Report from PCT application serial number PCT/US2004/39076, mailed April 20, 2005.
	Azzouz et al., "Lentiviral vectors for treating and modeling human CNS disorders", <u>J Gene Med</u> , 6(9), 951-962 (2004).
	Besnard et al., "Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein", <u>J Biol Chem</u> , 266(28), 18877-18883 (1991).
	Blömer et al., "Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector", <u>J Virol</u> , 71(9), 6641-6649 (1997).
	Brooks et al., "Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors", <u>PNAS</u> , 99(9), 6216-6221 (2002).
	Burton et al., "Gene therapy progress and prospects: Parkinson's disease", <u>Gene Ther</u> , 10(20), 1721-1727 (2003).
	Dylla et al., "Improved apical airway epithelia targeting properties of FIV vector pseudotyped with envelopes from LCMV", <u>Molecular Therapy</u> , 9, Supplement 1, page S186, abstract 491, (2004).
	Hsich et al., "Critical issues in gene therapy for neurologic disease", <u>Hum Gene Ther</u> , 13(5), 579-604 (2002).
	Loewen et al., "Transgene-specific toxicity in lentiviral vector-transduced feline TM in vivo", <u>ARVO Annual Meeting Abstract Search and Program Planner</u> , abstract 1147, Annual Meeting of the Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, USA, May 04-08, 2003 (2003).
	Petreanu et al., "Maturation and death of adult-born olfactory bulb granule neurons: Role of olfaction", <u>J Neurosci</u> , 22(14), 6106-6113 (2002).
	Rainov et al., "Clinical trials with retrovirus mediated gene therapy - what have we learned?", <u>J Neurooncol</u> , 65(3), 227-236 (2003).
	Sinnayah et al., "Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain", <u>Physiol Genomics</u> , 18(1), 25-32 (2004).

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)

* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO and/or 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number 10/718,262

Filing Date November 20, 2003

First Named Inventor McCray

Group Art Unit 1636

Examiner Name David Guzo

Sheet 2 of 2

Attorney Docket No: 17023.035US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", <u>Title of the Source</u> (book, magazine, journal, serial, symposium, catalog, etc.), <u>Volume-Number</u>, page(s) and (date).
	Stein et al., "Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors", <u>Methods Enzymol</u> , 346, 433-454 (2002).
	Stein et al., "The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain", <u>Mol Ther</u> , 11(3), 382-389 (2005).
	Verma et al., "Gene therapy -- promises, problems and prospects", <u>Nature</u> , 389(6648), 239-242 (1997).
	Wichterle et al., "Direct evidence for homotypic, glia-independent neuronal migration", <u>Neuron</u> , 18(5), 779-791 (1997).
	Wong et al., "Transduction patterns of pseudotyped lentiviral vectors in the nervous system", <u>Mol Ther</u> , 9(1), 101-111 (2004).

EXAMINER

DATE CONSIDERED